Panobinostat
- Generic Name
- Panobinostat
- Brand Names
- Farydak
- Drug Type
- Small Molecule
- Chemical Formula
- C21H23N3O2
- CAS Number
- 404950-80-7
- Unique Ingredient Identifier
- 9647FM7Y3Z
- Background
Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted. Panobinostat is mar...
- Indication
Panobinostat is indicated in the treatment of multiple myeloma in combination with dexamethasone and bortezomib in patients who have received 2 previous treatment regimens including bortezomib and an immunomodulatory agent. This indication is approved by accelerated approval based on progression free survival as of February 23, 2015.
- Associated Conditions
- Refractory Multiple Myeloma
- Associated Therapies
- -
Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis
- Conditions
- Interventions
- First Posted Date
- 2011-09-14
- Last Posted Date
- 2021-06-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 61
- Registration Number
- NCT01433445
- Locations
- 🇬🇧
Novartis Investigative Site, London, United Kingdom
Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors
- First Posted Date
- 2011-03-29
- Last Posted Date
- 2016-12-09
- Target Recruit Count
- 17
- Registration Number
- NCT01324635
- Locations
- 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2011-03-23
- Last Posted Date
- 2015-11-24
- Target Recruit Count
- 30
- Registration Number
- NCT01321346
- Locations
- 🇺🇸
UCSF School of Medicine, San Francisco, California, United States
🇺🇸Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸University of Miami Cancer Center, Miami, Florida, United States
Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2011-02-23
- Last Posted Date
- 2023-09-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 63
- Registration Number
- NCT01301807
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
- Conditions
- Adult Nasal Type Extranodal NK/T-cell LymphomaRecurrent Adult Burkitt LymphomaRecurrent Adult Lymphoblastic LymphomaRecurrent Adult T-cell Leukemia/LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Grade 3 Follicular LymphomaSplenic Marginal Zone LymphomaWaldenstrom MacroglobulinemiaAnaplastic Large Cell LymphomaAngioimmunoblastic T-cell Lymphoma
- Interventions
- First Posted Date
- 2010-12-16
- Last Posted Date
- 2022-05-24
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 41
- Registration Number
- NCT01261247
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- First Posted Date
- 2010-11-22
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- Abdullah Kutlar
- Target Recruit Count
- 18
- Registration Number
- NCT01245179
- Locations
- 🇺🇸
Augusta University, Augusta, Georgia, United States
Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)
- First Posted Date
- 2010-11-17
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 46
- Registration Number
- NCT01242774
- Locations
- 🇺🇸
Dana Farber Cancer Institute Beth Israel Deaconess Med Ctr, Boston, Massachusetts, United States
🇺🇸Medical University of South Carolina -Hollings Cancer Center MUSC/HCC (2), Charleston, South Carolina, United States
🇺🇸Vanderbilt University Medical Center, Clinical Trials Center Vanderbilt 3, Nashville, Tennessee, United States
Panobinostat and Fluorouracil Followed By Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer Who Did Not Respond to Previous Fluorouracil-Based Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2010-11-11
- Last Posted Date
- 2015-05-27
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 7
- Registration Number
- NCT01238965
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2010-07-26
- Last Posted Date
- 2021-01-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 62
- Registration Number
- NCT01169636
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Panobinostat, Etoposide, and Cisplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-07-12
- Last Posted Date
- 2014-12-31
- Lead Sponsor
- Cancer Trials Ireland
- Registration Number
- NCT01160731
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.